AlphAIalphai — Financial news for AI agents
aol.comAUG 263 min read$ARAY

Accuray (ARAY) Q4 2026 Earnings Call Transcript

Accuray (ARAY) reported Q4 2026 revenue of $100.9M, down 21% YoY, with product revenue declining 42% due to geopolitical tensions. Service revenue grew 6% to $60.1M. Full-year revenue was $401.9M, down 12%. The company realized $20M in cost savings and expects $15M more in FY27. Adjusted EBITDA was $12.9M, up from $9.4M YoY. Management cited trade policy uncertainty and regional volatility as risks.

Original reporting
aol.com
Published Aug 26, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Accuray (ARAY) Q4 2026 Earnings Call Transcript — source image
Source · aol.com
Decision brief

The 30-second read

$ARAYBearishHigh
01

Why it matters

The earnings release provides fresh quantitative data and management commentary, enabling traders to adjust positions based on the material decline in product revenue and lack of forward guidance.

02

Market read

First report of Accuray's Q4 earnings, indicating significant revenue contraction and strategic financing actions, relevant for medtech investors.

03

What to watch

Strong service gross margin improvement and backlog still sizable; could cushion earnings volatility.

Relevance 8/10Novelty 8/10Timing: post-earnings release

Background

Accuray disclosed its Q4 FY26 financial results, detailing revenue declines, cost savings, and strategic partnerships.

Company-level read

Ticker impact

$ARAYBearishHigh confidence
Context

Q4 FY26 earnings released with revenue down 21% YoY, product revenue down 42%, and no guidance due to geopolitical uncertainty.

Expected impact

Potential short-term price decline on earnings disappointment; watch for support around current levels.

Evidence & confidence

Revenue decline and absence of guidance are material new information that can affect investor sentiment immediately.

Market effects

Sector

Radiation therapy equipment sector faces pressure from China trade tensions.

Regional

US medtech investors may reassess exposure to companies with China revenue exposure.

Global

Highlights broader geopolitical risk to medtech supply chains.

Counterpoint

What could challenge this read

Cost-saving measures and service revenue growth could underpin a rebound if geopolitical risks ease.

Key entities

  • company
    Accuray Incorporated

    Medical device maker specializing in radiation therapy systems.

  • investor
    TCW Asset Management Company LLC

    Converted $40M term debt into preferred equity and provided $15M cash investment.

Read at source← All news

Related articles

AUG 28
$ARAYMed

Balance Sheet Rescue Meets China Drag in Accuray’s (ARAY) Mixed Quarter

Accuray (ARAY) reported a 21% revenue decline to $100.9M in Q4 2026, with China's market contributing to a 42% drop in product revenue. The company secured $60M in financing from TCW Asset Management, improving its balance sheet. Service revenue grew 6%, and cost savings exceeded targets. However, Accuray did not provide 2027 guidance due to trade policy uncertainties.

insidermonkey.com3 min
AUG 21
$ARAYMedAI 8/10

Accuray Incorporated Q4 2026 Earnings Call Summary

Accuray Incorporated reported Q4 2026 earnings, noting a $58M revenue decline due to China's geopolitical tensions. The company is shifting to a partner-centric model and saw 6% service revenue growth. Management highlighted clinical data validating their technology and $20M in cost improvements. No formal guidance was given for 2027 due to uncertainty. A debt-to-equity conversion with TCW and a reverse stock split plan were announced.

yahoo.com3 min
AUG 20
$ARAYHighAI 8/10

Accuray Inc (ARAY) (Q4 2026) Earnings Call Highlights: Strategic Transformation

Accuray Inc (ARAY) reported a 12% year-over-year revenue decline to $402M for fiscal 2026, with product revenue down 27% due to China sales drop. Gross margin fell to 27.7% from 32.1%, and operating loss was $26.4M. Management cited geopolitical tensions and tariff uncertainty. The company secured $55M in funding from TCW Asset Management, converting debt and receiving cash investment. Service revenue grew 4% year-over-year, and the company aims to improve cost structure and market reach in fisc

yahoo.com2 min
AUG 19
$ARAYHigh

ACCURAY INC (ARAY): Results of Operations and Financial Condition

ACCURAY INC (ARAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Accuray Reports Fourth Quarter and Fiscal 2026 Financial Results MADISON, Wisconsin, August 19, 2026 — Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2026 , ended June 30, 2026 . Key Highlights ● The Company’s t

SEC EDGAR 8-K2 min
JUL 29
$ARAYMedAI 8/10

Accuray Announces Plan Involving Financial Strengthening, Strategic Partnerships, Technology Rollouts, and Operational Initiatives to Drive Long-Term Value Creation

Accuray Inc. (NASDAQ: ARAY) said it reached definitive agreements with its primary lender and largest shareholder, TCW Asset Management, to delever $40 million via convertible preferred stock, add $15 million equity investment, and potentially access a delayed draw term loan up to $5 million. The plan includes covenant waivers through Dec. 31, 2027, board changes, and a reverse stock split. Accuray also outlined non-binding LOIs with Samsung HME America and RaySearch, plus expanded work with Tat

prnewswire.com6 min